ReviewMolecules (Basel, Switzerland)2008
Application of prodrugs to inflammatory diseases of the gut.
Review in Molecules (Basel, Switzerland), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Phospholipid-Prednisolone Conjugates for Targeted IBD Therapy: Structural Design, Synthetic Approaches, Optimization, and Computational Evaluation.Molecules (Basel, Switzerland) · 2026Article
- Preventive Effects ofFood science & nutrition · 2026Article
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Impact of gastric and bowel surgery on gastrointestinal drug delivery.Drug delivery and translational research · 2023Review
- Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2021Article
- Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors.Frontiers in pharmacology · 2020Review
- Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab.Diseases (Basel, Switzerland) · 2019Article
- Gut Microbiome and Response to Cardiovascular Drugs.Circulation. Genomic and precision medicine · 2019Review
- Review
- Treatment of inflammatory bowel disease via green tea polyphenols: possible application and protective approaches.Inflammopharmacology · 2018Review
- Chronic Inflammatory Diseases and Green Tea Polyphenols.Nutrients · 2017Review
- Design and Synthesis of Nanofibers of Self-assembledTetrahedron · 2016Article
- Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis.World journal of gastroenterology · 2014Article
- Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon.Frontiers in microbiology · 2014Review
- Developing a metagenomic view of xenobiotic metabolism.Pharmacological research · 2013Review
- Green Tea Polyphenols and Sulfasalazine have Parallel Anti-Inflammatory Properties in Colitis Models.Frontiers in immunology · 2013Article
- Osteopontin ablation attenuates progression of colitis in TNBS model.Digestive diseases and sciences · 2012Article
- The macrophage pattern recognition scavenger receptors SR-A and CD36 protect against microbial induced pregnancy loss.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2011Article
- Animal models for periodontal disease.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Oral delivery is the most common and preferred route of drug administration although the digestive tract exhibits several obstacles to drug delivery including motility and intraluminal pH profiles. The gut milieu represents the largest mucosal surface exposed to microorganisms with 10(10-12) colony forming bacteria/g of colonic content. Approximately, one third of fecal dry matter is made of bacteria/ bacterial components. Indeed, the normal gut microbiota is responsible for healthy digestion of dietary fibers (polysaccharides) and fermentation of short chain fatty acids such as acetate and butyrate that provide carbon sources (fuel) for these bacteria. Inflammatory bowel disease (IBD) results in breakage of the mucosal barrier, an altered microbiota and dysregulated gut immunity. Prodrugs that are chemically constructed to target colonic release or are degraded specifically by colonic bacteria, can be useful in the treatment of IBD. This review describes the progress in digestive tract prodrug design and delivery in light of gut metabolic activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.